F5 (Factor V) Leiden Gene Mutation Analysis

The factor V Leiden mutation, also designated as 1691 G>A or R506Q, is the major heritable risk factor for venous thromboembolism 1,2. This mutation in the coagulation factor V gene results in resistance of factor V to inactivation by activated protein C (APC)3-5. Approximately 5% of Caucasians are either heterozygous carriers or homozygous for the factor V Leiden mutation; the prevalences are lower for other ethnic groups 6,7.

To open a printable assay summary in a new window, click the link below.

Factor V Leiden Mutation Analysis Assay Summary
(in portable document format (pdf) which requires Adobe® Acrobat® Reader™ to view or print; download latest version free)

Please submit the Test Request Form (TRF).  

References
1. Voorberg, J. et al. (1994). Lancet 343:1535-1536.
2. Zoller, B. and Dahlback, B. (1994). Lancet 343:1536-1538.
3. Bertina, R. M. et al. (1994). Nature 369:64-67.
4. Greengard, J. S. et al. (1994). Lancet 343:1361-1362.
5. Sun, X. et al. (1994). Blood 83:3120-3125.
6. Gregg, J. P. et al. (1997). American Journal of Medical Genetics 73:334-336.
7. Ridker, P. M. et al. (1997). JAMA 277:1305-1307.

Back to the List of Services

NCI CCC LogoCity of Hope is one of 40 Comprehensive Cancer Centers, the highest designation bestowed by the National Cancer Institute and a recognition of excellence in cancer treatment, research, prevention and education.
City of Hope strongly supports and values the uniqueness of all individuals and promotes a work environment where diversity is embraced.
NCI CCC LogoThe National Comprehensive Cancer Network®
(NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HON code of the Healthcare on the Net Foundation.